Zymeworks (ZYME) Other Non-Current Assets (2021 - 2026)
Zymeworks (ZYME) reported Other Non-Current Assets of $6.7 million for Q1 2026, down 26.87% on a YoY basis from $9.1 million in Q1 2025, and little changed sequentially from $6.7 million in Q4 2025.
Zymeworks (ZYME) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Other Non-Current Assets data on file, last reported at $6.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 26.87% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (down 26.87% YoY), and the FY2025 full-year result was $6.7 million, down 25.17% from the prior year.
- Other Non-Current Assets was little changed at $6.7 million in Q1 2026, from $6.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $16.9 million in Q1 2023 to a low of $6.7 million in Q1 2026.
- A 5-year average of $9.5 million and a median of $7.9 million in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets climbed 25.93% in 2022 and sank 54.54% in 2024, its largest moves.
- Tracing ZYME's Other Non-Current Assets over 5 years: stood at $15.7 million in 2022, then tumbled by 51.9% to $7.6 million in 2023, then increased by 17.88% to $8.9 million in 2024, then declined by 25.17% to $6.7 million in 2025, then slipped by 0.33% to $6.7 million in 2026.
- Business Quant data shows ZYME's Other Non-Current Assets at $6.7 million in Q1 2026, $6.7 million in Q4 2025, and $7.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 14.48 Mn |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 8.86 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | 7.23 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 7.68 Mn |
| Dec 31, 2023 | 7.57 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 16.89 Mn |
| Dec 31, 2022 | 15.73 Mn |
| Sep 30, 2022 | 16.45 Mn |
| Dec 31, 2021 | 12.49 Mn |